Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of AV078 in Healthy Adults
NCT06205381Phase 1Completed
- Sponsor
- Aeovian Pharmaceuticals
- Start
- Jan 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AV078 in tuberous sclerosis complex (TSC) and epilepsy (4 arms), sponsored by Aeovian Pharmaceuticals. Primary endpoints: Incidence and severity of treatment emergent adverse events, Area under the concentration-time curve and 5 more. Started Jan 2024; status: completed.
02
Drugs
AV078
03
Conditions
tuberous sclerosis complex (TSC)epilepsy
Beyond the preview
Go deeper on NCT06205381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06205381.